Literature DB >> 18285522

Familial hypertrophic cardiomyopathy-related cardiac troponin C mutation L29Q affects Ca2+ binding and myofilament contractility.

Bo Liang1, Franca Chung, Yang Qu, Dmitri Pavlov, Todd E Gillis, Svetlana B Tikunova, Jonathan P Davis, Glen F Tibbits.   

Abstract

The cardiac troponin C (cTnC) mutation, L29Q, has been found in a patient with familial hypertrophic cardiomyopathy. We previously showed that L29, together with neighboring residues, Asp2, Val28, and Gly30, plays an important role in determining the Ca(2+) affinity of site II, the regulatory site of mammalian cardiac troponin C (McTnC). Here we report on the Ca(2+) binding characteristics of L29Q McTnC and D2N/V28I/L29Q/G30D McTnC (NIQD) utilizing the Phe(27) --> Trp (F27W) substitution, allowing one to monitor Ca(2+) binding and release. We also studied the effect of these mutants on Ca(2+) activation of force generation in single mouse cardiac myocytes using cTnC replacement, together with sarcomere length (SL) dependence. The Ca(2+)-binding affinity of site II of L29Q McTnC(F27W) and NIQD McTnC(F27W) was approximately 1.3- and approximately 1.9-fold higher, respectively, than that of McTnC(F27W). The Ca(2+) disassociation rate from site II of L29Q McTnC(F27W) and NIQD McTnC(F27W) was not significantly different than that of control (McTnC(F27W)). However, the rate of Ca(2+) binding to site II was higher in L29Q McTnC(F27W) and NIQD McTnC(F27W) relative to control (approximately 1.5-fold and approximately 2.0-fold respectively). The Ca(2+) sensitivity of force generation was significantly higher in myocytes reconstituted with L29Q McTnC (approximately 1.4-fold) and NIQD McTnC (approximately 2-fold) compared with those reconstituted with McTnC. Interestingly, the change in Ca(2+) sensitivity of force generation in response to an SL change (1.9, 2.1, and 2.3 mum) was significantly reduced in myocytes containing L29Q McTnC or NIQD McTnC. These results demonstrate that the L29Q mutation enhances the Ca(2+)-binding characteristics of cTnC and that when incorporated into cardiac myocytes, this mutant alters myocyte contractility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285522     DOI: 10.1152/physiolgenomics.00154.2007

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  33 in total

1.  A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation.

Authors:  Michelle S Parvatiyar; Andrew P Landstrom; Cicero Figueiredo-Freitas; James D Potter; Michael J Ackerman; Jose Renato Pinto
Journal:  J Biol Chem       Date:  2012-07-18       Impact factor: 5.157

2.  Cardiac troponin I tyrosine 26 phosphorylation decreases myofilament Ca2+ sensitivity and accelerates deactivation.

Authors:  Hussam E Salhi; Shane D Walton; Nathan C Hassel; Elizabeth A Brundage; Pieter P de Tombe; Paul M L Janssen; Jonathan P Davis; Brandon J Biesiadecki
Journal:  J Mol Cell Cardiol       Date:  2014-09-22       Impact factor: 5.000

Review 3.  The missing links within troponin.

Authors:  Mayra A Marques; Michelle S Parvatiyar; Wei Yang; Guilherme A P de Oliveira; Jose R Pinto
Journal:  Arch Biochem Biophys       Date:  2018-12-22       Impact factor: 4.013

4.  Changes in the dynamics of the cardiac troponin C molecule explain the effects of Ca2+-sensitizing mutations.

Authors:  Charles M Stevens; Kaveh Rayani; Gurpreet Singh; Bairam Lotfalisalmasi; D Peter Tieleman; Glen F Tibbits
Journal:  J Biol Chem       Date:  2017-05-22       Impact factor: 5.157

5.  Pathogenic peptide deviations support a model of adaptive evolution of chordate cardiac performance by troponin mutations.

Authors:  Nathan J Palpant; Evelyne M Houang; Wayne Delport; Kenneth E M Hastings; Alexey V Onufriev; Yuk Y Sham; Joseph M Metzger
Journal:  Physiol Genomics       Date:  2010-04-27       Impact factor: 3.107

6.  Influence of a constitutive increase in myofilament Ca(2+)-sensitivity on Ca(2+)-fluxes and contraction of mouse heart ventricular myocytes.

Authors:  Jose L Puglisi; Paul H Goldspink; Aldrin V Gomes; Megan S Utter; Donald M Bers; R John Solaro
Journal:  Arch Biochem Biophys       Date:  2014-01-27       Impact factor: 4.013

7.  Challenging current paradigms related to cardiomyopathies. Are changes in the Ca2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?

Authors:  David Dweck; Nir Hus; James D Potter
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

8.  Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C.

Authors:  Andrew P Landstrom; Michelle S Parvatiyar; Jose R Pinto; Michelle L Marquardt; J Martijn Bos; David J Tester; Steve R Ommen; James D Potter; Michael J Ackerman
Journal:  J Mol Cell Cardiol       Date:  2008-05-11       Impact factor: 5.000

Review 9.  Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies.

Authors:  Athanasia Kalyva; Fragiskos I Parthenakis; Maria E Marketou; Joanna E Kontaraki; Panos E Vardas
Journal:  J Muscle Res Cell Motil       Date:  2014-04-18       Impact factor: 2.698

10.  The cardiac troponin C mutation Leu29Gln found in a patient with hypertrophic cardiomyopathy does not alter contractile parameters in skinned murine myocardium.

Authors:  Axel Neulen; Robert Stehle; Gabriele Pfitzer
Journal:  Basic Res Cardiol       Date:  2009-06-09       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.